Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is planning to release its Q2 2021 financial report on Nov. 15, 2021. The report will cover the period ended Sept. 30, 2021. The company is also planning on hosting a conference call and webcast the same day, which is scheduled to begin at 4:30 p.m. EST. The call will be hosted by Cybin CEO Doug Drysdale and will provide an overview of the financial results along with relevant business updates. In addition, Drysdale and other team members will answer questions during the call. Those who want to participate in the call can dial 1-844-200-6205 toll free in the United States and 1-833-950-0062 toll free in Canada; the call code is 727873. An archived version of the call will also be available on the company’s investor relations site under the events & presentations page.
To view the webcast, visit https://ibn.fm/pc8F8
To view the full press release, visit https://ibn.fm/9M9eJ
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, is on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork